금융 뉴스 허브

Cigna Investor Day Spotlights Specialty Drugs

Cigna Group investors will be looking for more detail on the growth of its specialty pharmacy business under new CEO Brian Evanko.

Is CrowdStrike Stock Paying You Enough For The Swings?

You may own CrowdStrike (CRWD), a cybersecurity company whose shares rose 5.1% in five sessions as the S&P 500 fell 1.2%. You likely hold it beside an index fund, and your whole account swings more wh ...

Why Tesla’s $25 Billion Credit Line Is a High-Stakes Bet on AI and Robotaxis

Tesla is set to borrow a lot more money as it invests heavily in its AI ambitions. Tuesday, the EV maker entered into $25 billion in new credit facilities, including a $20 billion three-year delayed ...

Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter

Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.

3 Reasons to Sell FRPT and 1 Stock to Buy Instead

Freshpet currently trades at $57.15 per share and has shown little upside over the past six months, posting a middling return of 1%. The stock also fell short of the S&P 500’s 21.1% gain during that p ...

Prediction: A Stock Market Crash Is Coming. Here's the 1 Growth Stock I'd Buy Anyway.

Market valuations are unusually high.

Nvidia CEO Jensen Huang was everywhere in Q3. The AI giant's stock proves it.

Shares of Nvidia are on track to surge 17% in the third quarter, which officially comes to a close today.

2 Reasons to Watch KO and 1 to Stay Cautious

While the S&P 500 is up 21.1% since March 2026, Coca-Cola (currently trading at $87.00 per share) has lagged behind, posting a return of 14.1%. This may have investors wondering how to approach the si ...

Pharmaceutical industry lobbying group names new CEO, Eric Cantor

What Is Merck Stock's Biggest Opportunity?

Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 ...

Barclays downgrades Mobileye, cites lack of progress on advanced wins

Investing.com -- Barclays downgraded Mobileye to Equal Weight from Overweight and cut its price target to $9 from $14 per share in a note on Wednesday, saying the company has not landed enough advance ...

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.